Биология ва тиббиёт муаммолари 2025, №1 (158)

Subject of the article

СУРУНКАЛИ БУЙРАК КАСАЛЛИГИНИ ҲАЙВОН МОДЕЛЛАРИ ОРҚАЛИ ЎРГАНИШ (319-324)

Authors

Тилавов Толибжон Бахтиёр ўғли

Institution

Бухоро давлат тиббиёт институти, Ўзбекистон Республикаси, Бухоро ш.

Abstract

Сурункали буйрак касаллиги бугунги кунда дунё соғлиқни сақлаш тизими учун катта хавотир бўлиб, кўплаб хасталиклар учун касалланиш ва ўлимга олиб келувчи мустақил хавф омилларидан биридир. Дунё бўйлаб СБК нинг тахминий тарқалиши барча ёш гуруҳларида 9,1% (697,5 million ҳолат) ни ташкил қилади ва 1,2 миллионга яқин киши шу касаллик оқибатида 2017-йилда вафот этган. Протеинурия ва гломеруляр филтрация тезлигининг(ГФТ) пасайиши буйрак шикастланишининг асосий кўрсаткичидир. СБК нинг тарқалиш даражасини баҳолашда ишончли моделларга эҳтиёж катта. Ҳайвон моделлар мураккаб касаллик патофизиологиясини таҳлил қилиш, СБК ҳолатларида янги дорилар ва аралашувларни киритиш имконини беради[52]. Турли моделларни ўрганиш СБК сабабига мос келадиган аниқ моделни танлашда ёрдам беради.

Key words

Алпорт синдроми. СБК, калсификация, ГФТ, Нефрэктомия, буйрак поликистози, глицерин, деоксикортостерон ацетат.

Literature

1. Cornelia Charles, Allison H. Ferris. Chronic Kidney Disease, Primary Care: Clinics in Office Practice. 2020;47(8):585-595. 2. Xinling Song, Hui Pang, Weijun Cui, Jianjun Zhang, Jian Li, Le Jia. Renoprotective effects of enzyme-hydrolyzed polysaccharides from Auriculariapolytricha on adenine-induced chronic kidney diseases in mice.Biomedicine& Pharmacotherapy. 2021;135: 111004. 3. Yen-Cheng Chen, Chung-Yi Cheng, Chung-Te Liu, Yuh-Mou Sue, Tso-Hsiao Chen, Yung-Ho Hsu, Nai-Jen Huang, Cheng-Hsien Chen. Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice. European Journal of Pharmacology. 2021; 892:173708. 4. SidarCopur, Emine M. Onal, BarisAfsar, Alberto Ortiz, Daniel H. van Raalte, David Z. Cherney, Peter Rossing, Mehmet Kanbay. Diabetes mellitus in chronic kidney dis-ease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. Journal of Diabetes and its Complications. 2020; 34(11):107707. 5. Adam J. Nelson, Paolo Raggi, Myles Wolf, Alexander M. Gold, Glenn M. Chertow, Matthew T. Roe.Targeting Vascular Calcification in Chronic Kidney Disease. JACC: Basic to Translational Science. 2020;5(4):398-412 6. Palit S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des. 2014;20(37):5829-5833. 7. Xiaorong Han, Shuai Zhang, Zhongbo Chen, Binay Kumar Adhikari, Ying Zhang, Jin Zhang, Jian Sun, Yonggang Wang. Cardiac biomarkers of heart failure in chronic kidney disease. Clinica Chimica Acta. 2020; 510:298-310. 8. Mark Fisher,Mechanisms of Cerebral Microvascular Disease in Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases. 2020;105404. 9. Charlie Tomson, Samuel Duffy. Management of chronic kidney disease. Medicine. 2019;47(9): 567-575. 10. Maaz Syed - Ahmed , Mohanram Nara-yanan,Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Advances in Chronic Kidney Disease. 2019;26(1): 8-15. 11. Dai, C., Kiss, L. P., & Liu, Y. Animal Models of Kidney Diseases. Sourcebook of Models for Biomedical Research. 2008;657–664. 12. Zahraa Mohammed-Ali, Rachel E. Carlisle, SameraNademi, Jeffrey G. Dickhout, Chapter 16 - Animal Models of Kidney Disease. 2017;379-417. 13. Luo W-m, Kong J, Gong Y, Liu X-q, Yang R-x, Zhao Y-x. Tongxinluo Protects against Hypertensive Kidney Injury in Spontaneously Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead Box O1 Signal-ing. PLoS ONE. 2015; 10(12): e0145130. 14. Hai-Yan Xue, Li Yuan, Ying-Jie Cao, Ya-Ping Fan, Xiao-Lan Chen, Xin-ZhongHuang. Resveratrol amelio-rates renal injury in spontaneously hypertensive rats by inhibiting renal microinflammation. Biosci Rep. 2016; 36 (3): e00339. 15. David A. Blizard, Wanda N. Peterson, Samy S.Iskandar, Z. K. Shihabi & Nelson Adams. The Effect of a High Salt Diet and Gender on Blood Pressure, Urinary Protein Excretion and Renal Pathology in Shr Rats. Clini-cal and Experimental Hypertension Part A: Theory and Practice. 1991;13(5):687-697. 16. Subrata K. Biswas, Jose B. Lopes De Faria, Subrata K. Biswas & Jose B. Lopes De Faria. Which comes first: Re-nal inflammation or oxidative stress in spontaneously hy-pertensive rats? Free Radical Research. 2007;41(2):216-224. 17. Hewitson TD, Ono T, Becker GJ. Small animal models of kidney disease: a review. Methods Mol Biol. 2009;466:41-57. 18. Mumna Al Banchaabouchi, Bart Marescau, Rudi D’Hooge, Eric Van Marck, Andre Van Daele, Olivier Levillain, Peter Paul De Deyn. Biochemical and histopathological changes in nephrectomized mice. Me-tabolism. 1998;47(3):355-361. 19. Rui-Zhi Tan, Xia Zhong, Jian-Chun Li, Yu-Wei Zhang, Ying Yan, Yuan Liao, Dan Wen, Hui Diao, Li Wang & Hong-Chun Shen.An optimized 5/6 nephrectomy mouse model based on unilateral kidney ligation and its applica-tion in renal fibrosis research. Renal Failure. 2019;41(1): 555-566. 20. Jorge Montes-Rivera, Mónica Arellano-Mendoza, NayelliNájera, Leonardo Del Valle-Mondragón, Francisco Villarreal, Ivan Rubio-Gayosso, Javier Perez-Duran, Edu-ardo Meaney, Guillermo Ceballos.Effect of (-)-epicatechin on the modulation of progression markers of chronic renal damage in a 5/6 nephrectomy experimental model. Heliyon. 2019;5(4):e01512. 21. Christian Fleck, Dorothea Appenroth, Patrick Jonas, Mark Koch, GüntherKundt, Horst Nizze, Günter Stein.Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats – Influence of sex, strain, and surgical procedure. Ex-perimental and Toxicologic Pathology. 2006;57(3):195-205. 22. Ashok Jadhav, Emina Torlakovic, and Joseph Fomusi Ndisang. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Ameri-can Journal of Physiology-Renal Physiology. 2009; 296(3):F521-F534. 23. Ndisang JF, Lane N, Jadhav A. Crosstalk between the hemeoxygenase system, aldosterone, and phospholipase C in hypertension. J Hypertens. 2008; 26(6):1188-99. 24. Jadhav A, Torlakovic E, Ndisang JF.Interaction among hemeoxygenase, nuclear factor-êB, and transcription acti-vating factors in cardiac hypertrophy in hypertension. Hypertension.2008;52: 910–917. 25. Lu Jiandong, Yilong Yang, JintingPeng, Min Xiang, Dongcai Wang, GuoliangXiong, Shunmin Li, Trichosantheskirilowii. lectin ameliorates streptozocin-induced kidney injury via modulation of the balance be-tween M1/M2 phenotype macrophage. Biomedicine& Pharmacotherapy. 2019;109:93-102. 26. Benhong Zhou, Qiaoling Li, Jing Wang, Peng Chen, Shan Jiang.Ellagic acid attenuates streptozocin induced diabetic nephropathy via the regulation of oxidative stress and inflammatory signaling, Food and Chemical Toxicology. 2019;123:16-27 27. Amit Kundu, PrasantaDey, Pradipta Sarkar, SanmoyKarmakar, In Hwan Tae, Kyeong Seok Kim, Jae Hyeon Park, Su Hyun Lee, Byung Mu Lee, LalmuanawmiRenthlei, ZothanPuia, HyungSik Kim. Pro-tective effects of Croton hookeri on streptozotocin-induced diabetic nephropathy. Food and Chemical Toxi-cology. 2020;135:110873. 28. Li Jie, QiuPengcheng, He Qiaoyan, Bi Linlin, Zhang Meng, Wang Fang, Jia Min, Yan Li, Zhang Ya, Yang Qian, Wang Siwang.Dencichine ameliorates kidney injury in induced type II diabetic nephropathy via the TGF-â/Smadsignalling pathway. European Journal of Pharma-cology. 2017; 812:196-205. 29. Solomon Oladapo Rotimi, OluwakemiAnuoluwapoRotimi, Isaacson BababodeAdelani, ChinonyeOnuzulu, Patience Obi, RotimiOkungbaye.Stevioside modulates oxidative damage in the liver and kidney of high fat/low streptozocin diabetic rats. Heliyon.2018;4(5):e00640. 30. Anna Giralt-Lopez ,Mireia Molina, Van den Bosch. Revisiting Experimental Models of Diabetic Nephropathy. Int. J. Mol. Sci. 2020; 21:3587. 31. Eman Mostafa Sadek, Nagla Mohamed Salama, Dalia Ibrahim Ismail, Asmaa Ahmed Elshafei. Histological study on the protective effect of endogenous stem-cell mobilization in Adriamycin-induced chronic nephropathy in rats. Journal of Microscopy and Ultrastructure.2016;4(3):133-142. 32. Minggang Wei, Wei Sun, Weiming He, Li Ni, Xiaofeng Cai, Zongqi Cheng, Kun Gao, Fengling Li, Lin Chen, Xinping Zhang.Qiguiyishen decoction reduced the accumulation of extracellular matrix in the kidneys of rats with adriamycin-induced nephropathy. Journal of Tradi-tional Chinese Medicine. 2014;34(3):351-356. 33. Sachinthi S. Amarasiri, Anoja P. Attanayake, Liyanagae D.A.M. Arawwawala, Kamani A.P.W. Jayatilaka, Lakmini K.B. Mudduwa.Protective effects of three selected standardized medicinal plant extracts used in Sri Lankan traditional medicine in adriamycin induced nephrotoxic Wistarrats. Journal of Ethnopharmacology. 2020;259:112933. 34. Yitian Dou, Yichun Shang, YongmeiShen, JingtianQu, Chunliu Liu, JiasongCao.Baicalin alleviates adriamycin-induced focal segmental glomerulosclerosis and pro-teinuria by inhibiting the Notch1-Snail axis mediated podocyteEMT. Life Sciences. 2020;257:118010. 35. Badreldin H. Ali, Mohammed Al Za’abi, Sirin A. Adham, Yousuf Al Suleimani, TuranKaraca, PriyadarsiniManoj, Jamila Al Kalbani, JavidYasin, AbderrahimNemmar.The effect of sildenafil on rats with adenine—Induced chronic kidney disease. Biomedicine& Pharmacotherapy.2018;108:391-402. 36. Diwan, V., Brown, L. and Gobe, G.C..Adenine induced chronic kidney disease in rats. Nephrology. 2018; 23: 5-11. 37. Aly M. Abdelrahman, Yousuf Al Suleimani, Moham-med Al Za’abi, Mohammed Ashique, PriyadarsiniManoj, Christina Hartmann, AbderrahimNemmar, Nicole Schupp, Badreldin H. Ali.Therenoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenineinduced kidney disease in rats. Biomedicine & Pharmacotherapy. 2019;110:667-676. 38. Anshuk Sharma, Richa Thakur, Madhu C. Lingaraju, Dhirendra Kumar, KarikalanMathesh, Avinash G. Telang, Thakur Uttam Singh, Dinesh Kumar.Betulinic acid attenu-ates renal fibrosis in rat chronic kidney disease model. Bi-omedicine& Pharmacotherapy. 2017;89:796-804. 39. Amarasiri S S, Attanayake A P, Jayatilaka K A, Mudduwa L K. Animal models of chronic kidney disease: Screening tool to investigate nephroprotective effects of natural products. Int J Pharm Chem Anal. 2018;5(2):52-58 40. Naoko Takeda, Shinji Kume, Yuki Tanaka, YoshikataMorita,Masami Chin-Kanasaki, Hisazumi Araki, KeijiIsshiki,ShinichiAraki,MasakazuHaneda,y Daisuke Koya, z Atsunori Kashiwagi,HiroshiMaegawa, and Ta-kashi Uzu.Altered Unfolded Protein Response Is Implicat-ed in the Age-Related Exacerbation of Proteinuria-Induced Proximal Tubular Cell Damage. American journal of pathology. 2013;183:774-785. 41. Shixin Ding, Han Zhang, Zhenghao Sun, Yuli Han, Yan Li, Xianan Dong, Yanyan Yin, Weiping Li, WeizuLi.Ginsenoside Rg1 protects against aging-induced renal interstitial fibrosis due to inhibition of tubular epi-thelial cells endoplasmic reticulum stress in SAMP8 mice. Journal of Functional Foods. 2020;72:104049. 42. Sugyeong Ha, Min Jo Kim, Dae Hyun Kim, Byeong Moo Kim, Ki Wung Chung, Hae Young Chung.Short-term intake of high fat diet aggravates renal fibrosis in aged Sprague Dawleyrats. Experimental Gerontolo-gy.2020;142:111108. 43. Jing Gong, Ami Tamhaney, Mohanraj Sadasivam, Hamid Rabb, Abdel Rahim A.Hamad. Chapter 68 - Autoimmune Diseases in the Kidney,Editor(s): Noel R. Rose, Ian R. Mackay.The Autoimmune Diseases (Sixth Edition), Academic Press.2020;1355-1366. 44. MårtenSegelmark, Thomas Hellmark. Autoimmune kidney diseases. Autoimmunity Reviews. 2010;9:A366–A371. 45. Alberto de Zubiria Salgado, Catalina HerreraDiaz. Lu-pus Nephritis: An Overview of Recent Findings. Autoim-mune Diseases. 2012; 46. J.P. Gaut. Immune-Mediated Glomerular Injury. Pathobiology of Human Disease. Academic Press:2014; 2788-2801. 47. Jefferson JA, Pippin JW, Shankland SJ. Experimental Models of Membranous Nephropathy. Drug Discov Today Dis Models. 2010;7(1-2):27-33. 48. Mary H. Foster.Optimizing the translational value of animal models of glomerulonephritis: insights from recent murine prototypes, Am J Physiol Renal Physiol. 2016; 311: F487–F495. 49. Dorin-Bogdan Borza and Billy G. Hudson. Of mice and men: Murine models of anti-GBM antibody nephritis. Kidney International. 2002; 61:1905–1906. 50. Борисова, И. В., & Штрыголь, С. Ю. (2003). Ре-нальные и нейропротекторные эффекты перфторана на модели токсического поражения почек крыс. Росс. биомедиц. журнал, 5, 136-139. 51. Джиоев, И. Г., Хубулов, И. Г., Клочков, Д. А., & Батагов, Ф. Э. (2014). Влияние дофамина на водовыде-лительную функцию почек при экспериментальной острой почечной недостаточности. Современные про-блемы науки и образования, (1), 118-118. 52. Shizuko Nagao, Masanori Kugita, Daisuke Yoshihara, and Tamio Yamaguchi. Animal Models for Human Poly-cystic Kidney Disease. Exp. Anim. 2012; 61(5):477–488.